<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313209</url>
  </required_header>
  <id_info>
    <org_study_id>BY217/M2-127</org_study_id>
    <secondary_id>2005-005080-28</secondary_id>
    <nct_id>NCT00313209</nct_id>
  </id_info>
  <brief_title>Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)</brief_title>
  <acronym>EOS</acronym>
  <official_title>Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the efficacy of roflumilast on pulmonary function and
      symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during
      concomitant administration of salmeterol. The study duration will last up to 28 weeks. The
      study will provide further data on safety and tolerability of roflumilast.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)</measure>
    <time_frame>Change from baseline over 24 weeks of treatment</time_frame>
    <description>Mean change from baseline during the treatment period in pre-bronchodilator FEV1 [L]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FEV1</measure>
    <time_frame>Change from baseline over 24 weeks of treatment</time_frame>
    <description>Mean change from baseline during the treatment period in post-bronchodilator FEV1 [L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Exacerbation Rate (Mild, Moderate or Severe)</measure>
    <time_frame>24 weeks treatment period</time_frame>
    <description>Mean rate of COPD exacerbations requiring rescue medication of 3 or more puffs/day on at least 2 consecutive days (=mild COPD exacerbations), or requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management [ATS / ERS 2005].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index (TDI) Focal Score</measure>
    <time_frame>Change from baseline over 24 weeks of treatment</time_frame>
    <description>The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shortness of Breath Questionnaire (SOBQ) Total Score</measure>
    <time_frame>Change from baseline over 24 weeks of treatment</time_frame>
    <description>Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is &quot;not at all breathless&quot; and five is &quot;maximally breathless or too breathless to do the activity&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">933</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roflumilast 500 µg
underlying medication: salmeterol 50 μg, twice daily, inhaled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo
underlying medication: salmeterol 50 μg, twice daily, inhaled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>500 µg, once daily, oral administration in the morning</description>
    <arm_group_label>Roflumilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  History of COPD for at least 12 months prior to baseline visit

          -  FEV1/FVC ratio (post-bronchodilator) ≤ 70%

          -  FEV1 (post-bronchodilator) between ≥ 40% and ≤ 70% of predicted

        Main Exclusion Criteria:

          -  COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or
             antibiotics not stopped at least 4 weeks prior to baseline visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Neusiedl/See</city>
        <zip>7100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Perg</city>
        <zip>4320</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>St. Pölten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1150</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Zwettl</city>
        <zip>3910</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1040</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Duffel</city>
        <zip>2570</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Halen</city>
        <zip>3545</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Malmedy</city>
        <zip>4960</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Montigny-Le-Tilleul</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Veurne</city>
        <zip>8630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ajax, Ontario</city>
        <zip>L1S 2J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Halifax, N.S.</city>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hamilton, Ontario</city>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Laval</city>
        <zip>H7V3Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>London</city>
        <zip>N6A 5R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mirabel</city>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Montreal, PQ</city>
        <zip>H2X2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Montreal</city>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>New Market, ON</city>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>North Bay</city>
        <zip>P1B2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ontario</city>
        <zip>L4C3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Quebec City</city>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Regina, Saskatchewan</city>
        <zip>S4P 1Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Saint John</city>
        <zip>E2K2T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sainte-Foy, Quebec</city>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Saskatoon SK</city>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sherbrooke, PQ</city>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Toronto, ON</city>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Toronto, ON</city>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Vancouver, BC</city>
        <zip>V6S 3J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Windsor</city>
        <zip>N8X 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Winnipeg MB</city>
        <zip>R2K 3S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <zip>N4S 4G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Beausoleil</city>
        <zip>6240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Beuvry</city>
        <zip>62660</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Chauny Cedex</city>
        <zip>2303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Grasse</city>
        <zip>6130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Martigues Cedex</city>
        <zip>13695</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Montpellier Cedex</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Nice Cedex 1</city>
        <zip>6002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>6000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Nimes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Saint Laurent Du Var</city>
        <zip>6700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Saint-Quentin</city>
        <zip>2100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Trelaze</city>
        <zip>49800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bonn</city>
        <zip>53119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Geesthacht</city>
        <zip>21502</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Gelnhausen</city>
        <zip>63571</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Köln</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Schwetzingen</city>
        <zip>68723</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sinsheim</city>
        <zip>74889</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Surwold</city>
        <zip>26903</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bologna</city>
        <zip>48138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Catania</city>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Cisanello (PI)</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Genova</city>
        <zip>16100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Livorno</city>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Saluzzo (CN)</city>
        <zip>12037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Tradate (VA)</city>
        <zip>21049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Verona</city>
        <zip>30012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Vittorio Veneto (TV)</city>
        <zip>31029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Helmond</city>
        <zip>5707 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Schiedam</city>
        <zip>3116 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Sites</name>
      <address>
        <city>Kapstadt</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Alicante</city>
        <zip>3550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Elche (Alicante)</city>
        <zip>3202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Fuentesnuevas, Ponferrada (León)</city>
        <zip>24411</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Laredo (Cantabria)</city>
        <zip>39770</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mataró, Barcelona</city>
        <zip>8303</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Petrer (Alicante)</city>
        <zip>3610</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Tarrasa (Barcelona)</city>
        <zip>8221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Torrelavega (Cantabria)</city>
        <zip>39300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT14 6AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT15 2GE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT7 1DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bexhill-on-Sea, East Sussex</city>
        <zip>TN40 1JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bradford on Avon, Wiltshire</city>
        <zip>BA15 1DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD157NJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Chesterfield Derbyshire</city>
        <zip>S40 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Coleraine</city>
        <zip>BT52 1HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Cookstown</city>
        <zip>BT80 8BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>East Sussex</city>
        <zip>TN39 5HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Edinburg</city>
        <zip>EH8 9AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G3 8YJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hastings</city>
        <zip>TN34 3EY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Middlessex</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sunbury on Thames, Middlessex</city>
        <zip>TW16 6RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Watford</city>
        <zip>WD25 0EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009 Aug 29;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6.</citation>
    <PMID>19716961</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2006</study_first_submitted>
  <study_first_submitted_qc>April 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <results_first_submitted>March 17, 2011</results_first_submitted>
  <results_first_submitted_qc>April 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2011</results_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Roflumilast</keyword>
  <keyword>Salmeterol</keyword>
  <keyword>COPD</keyword>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Roflumilast</title>
          <description>Roflumilast 500 µg, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="466">Includes all randomized patients who took at least one dose of the investigational drug.</participants>
                <participants group_id="P2" count="467">Includes all randomized patients who took at least one dose of the investigational drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="385"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Roflumilast</title>
          <description>Roflumilast 500 µg, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="466"/>
            <count group_id="B2" value="467"/>
            <count group_id="B3" value="933"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="8.7"/>
                    <measurement group_id="B2" value="64.9" spread="9.3"/>
                    <measurement group_id="B3" value="64.9" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="319"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)</title>
        <description>Mean change from baseline during the treatment period in pre-bronchodilator FEV1 [L]</description>
        <time_frame>Change from baseline over 24 weeks of treatment</time_frame>
        <population>ITT (Intention to Treat) analysis. Number of participants analyzed = number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Roflumilast 500 µg, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)</title>
          <description>Mean change from baseline during the treatment period in pre-bronchodilator FEV1 [L]</description>
          <population>ITT (Intention to Treat) analysis. Number of participants analyzed = number of participants with data available.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="463"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="9"/>
                    <measurement group_id="O2" value="-10" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No adjustment of the significance level (0.05) was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Repeated measurements analysis (change from baseline over 24 weeks of treatment taking all post-randomization measurements into account).</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27</ci_lower_limit>
            <ci_upper_limit>71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FEV1</title>
        <description>Mean change from baseline during the treatment period in post-bronchodilator FEV1 [L]</description>
        <time_frame>Change from baseline over 24 weeks of treatment</time_frame>
        <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Roflumilast 500 µg, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FEV1</title>
          <description>Mean change from baseline during the treatment period in post-bronchodilator FEV1 [L]</description>
          <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" spread="9"/>
                    <measurement group_id="O2" value="8" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No adjustment of the significance level (0.05) was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Repeated measurements analysis (change from baseline over 24 weeks of treatment taking all post-randomization measurements into account).</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>38</ci_lower_limit>
            <ci_upper_limit>82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Exacerbation Rate (Mild, Moderate or Severe)</title>
        <description>Mean rate of COPD exacerbations requiring rescue medication of 3 or more puffs/day on at least 2 consecutive days (=mild COPD exacerbations), or requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management [ATS / ERS 2005].</description>
        <time_frame>24 weeks treatment period</time_frame>
        <population>ITT analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Roflumilast 500 µg, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Exacerbation Rate (Mild, Moderate or Severe)</title>
          <description>Mean rate of COPD exacerbations requiring rescue medication of 3 or more puffs/day on at least 2 consecutive days (=mild COPD exacerbations), or requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management [ATS / ERS 2005].</description>
          <population>ITT analysis</population>
          <units>exacerbations per patient per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.5" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.9" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1408</p_value>
            <p_value_desc>No adjustment of the significance level (0.05) was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>Poisson regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transition Dyspnea Index (TDI) Focal Score</title>
        <description>The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from –3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from –9 to +9.</description>
        <time_frame>Change from baseline over 24 weeks of treatment</time_frame>
        <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Roflumilast 500 µg, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
        </group_list>
        <measure>
          <title>Transition Dyspnea Index (TDI) Focal Score</title>
          <description>The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from –3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from –9 to +9.</description>
          <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="454"/>
                <count group_id="O2" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.1"/>
                    <measurement group_id="O2" value="1.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4654</p_value>
            <p_value_desc>No adjustment of the significance level (0.05) was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Repeated measurements analysis (change from baseline over 24 weeks of treatment taking all post-randomization measurements into account).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shortness of Breath Questionnaire (SOBQ) Total Score</title>
        <description>Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is &quot;not at all breathless&quot; and five is &quot;maximally breathless or too breathless to do the activity&quot;.</description>
        <time_frame>Change from baseline over 24 weeks of treatment</time_frame>
        <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Roflumilast 500 µg, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
          </group>
        </group_list>
        <measure>
          <title>Shortness of Breath Questionnaire (SOBQ) Total Score</title>
          <description>Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is &quot;not at all breathless&quot; and five is &quot;maximally breathless or too breathless to do the activity&quot;.</description>
          <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="454"/>
                <count group_id="O2" value="461"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.7"/>
                    <measurement group_id="O2" value="-1.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5457</p_value>
            <p_value_desc>No adjustment of the significance level (0.05) was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Repeated measurements analysis (change from baseline over 24 weeks of treatment taking all post-randomization measurements into account).</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks treatment period</time_frame>
      <desc>The Safety Set was based on all randomized patients who took at least one dose of the investigational drug after randomization.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roflumilast</title>
          <description>Roflumilast 500 µg, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, once daily, oral and salmeterol 50 µg, twice daily, inhaled</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="466"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Retinitis pigmentosa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Meningorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="466"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="466"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>non-serious</description>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="466"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="467"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="466"/>
                <counts group_id="E2" events="43" subjects_affected="35" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <description>non-serious</description>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="466"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <description>non-serious</description>
                <counts group_id="E1" events="81" subjects_affected="70" subjects_at_risk="466"/>
                <counts group_id="E2" events="126" subjects_affected="103" subjects_at_risk="467"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The study results may be published and/or presented at scientific meetings. Prior to any submission, all manuscripts/abstracts must be presented to the sponsor for possible comments.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical Study Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

